Japanese drugmaker Kyowa Kirin Co., Ltd. reported a 10.2% rise in revenue to ¥384.95 billion for the first nine months of 2026 and maintained its full-year outlook.
The revenue figure covers the period ended Sept. 30 and compares with the same nine months of 2025. Kyowa Kirin also reported non-GAAP earnings per share of ¥147.83 for the period. The per-share measure follows the company’s own calculation method.
The unchanged outlook applies to all of 2026; the reported revenue and earnings-per-share figures cover only the first nine months.
